CytoSorbents Corp (NASDAQ:CTSO) Reports Mixed Q2 2025 Earnings with Revenue Beat and Narrower Loss

CytoSorbents Corp (NASDAQ:CTSO) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company, which specializes in blood purification technologies for critical care, posted revenue of $9.62 million, slightly above the consensus estimate of $9.42 million. Earnings per share (EPS) came in at -$0.05, marginally better than the anticipated -$0.051.

Key Financial Highlights

• Revenue Beat: The $9.62 million in sales for Q2 2025 exceeded expectations by approximately 2.1%, reflecting steady demand for the company’s flagship product, CytoSorb, and other critical care solutions.
• Narrower Loss Than Expected: While still unprofitable, the EPS loss of $0.05 was slightly better than the projected -$0.051, suggesting some cost control or revenue mix benefits.
• Market Reaction: Following the earnings release, shares rose 4.32% in after-hours trading, indicating investor optimism about the modest beat. However, the stock remains down 18.7% over the past month, reflecting broader market skepticism or sector-specific pressures.

Business Update Highlights

The press release emphasized CytoSorbents’ ongoing commercialization efforts for CytoSorb, particularly in intensive care and cardiac surgery applications. The company continues to expand its clinical footprint, though no major regulatory or partnership announcements were disclosed in this update.

Forward-Looking Estimates vs. Market Sentiment

Analysts project full-year 2025 revenue at $39.56 million, with an estimated EPS loss of -$0.16. For Q3 2025, expectations stand at $10.23 million in revenue and an EPS loss of -$0.044. The after-hours bounce suggests traders see potential for stabilization, but the stock’s longer-term downtrend indicates lingering concerns over profitability and growth sustainability.

For a deeper dive into CytoSorbents’ earnings and analyst estimates, visit the earnings page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.